Cargando…

Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature

BACKGROUND: WHO’s Global Programme to Eliminate Lymphatic Filariasis (LF) uses mass drug administration (MDA) of anthelmintic medications to interrupt LF transmission in endemic areas. Recently, a single dose combination of ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ALB) was shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Budge, Philip J., Herbert, Carly, Andersen, Britt J., Weil, Gary J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973625/
https://www.ncbi.nlm.nih.gov/pubmed/29768412
http://dx.doi.org/10.1371/journal.pntd.0006454
_version_ 1783326670279671808
author Budge, Philip J.
Herbert, Carly
Andersen, Britt J.
Weil, Gary J.
author_facet Budge, Philip J.
Herbert, Carly
Andersen, Britt J.
Weil, Gary J.
author_sort Budge, Philip J.
collection PubMed
description BACKGROUND: WHO’s Global Programme to Eliminate Lymphatic Filariasis (LF) uses mass drug administration (MDA) of anthelmintic medications to interrupt LF transmission in endemic areas. Recently, a single dose combination of ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ALB) was shown to be markedly more effective than the standard two-drug regimens (DEC or IVM, plus ALB) for achieving long-term clearance of microfilaremia. OBJECTIVE AND METHODS: To provide context for the results of a large-scale, international safety trial of MDA using triple drug therapy, we searched Ovid Medline for studies published from 1985–2017 that reported adverse events (AEs) following treatment of LF with IVM, DEC, ALB, or any combination of these medications. Studies that reported AE rates by treatment group were included. FINDINGS: We reviewed 162 published manuscripts, 55 of which met inclusion criteria. Among these, 34 were clinic or hospital-based clinical trials, and 21 were community-based studies. Reported AE rates varied widely. The median AE rate following DEC or IVM treatment was greater than 60% among microfilaremic participants and less than 10% in persons without microfilaremia. The most common AEs reported were fever, headache, myalgia or arthralgia, fatigue, and malaise. INTERPRETATION: Mild to moderate systemic AEs related to death of microfilariae are common following LF treatment. Post-treatment AEs are transient and rarely severe or serious. Comparison of AE rates from different community studies is difficult due to inconsistent AE reporting, varied infection rates, and varied intensity of follow-up. A more uniform approach for assessing and reporting AEs in LF community treatment studies would be helpful.
format Online
Article
Text
id pubmed-5973625
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59736252018-06-08 Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature Budge, Philip J. Herbert, Carly Andersen, Britt J. Weil, Gary J. PLoS Negl Trop Dis Research Article BACKGROUND: WHO’s Global Programme to Eliminate Lymphatic Filariasis (LF) uses mass drug administration (MDA) of anthelmintic medications to interrupt LF transmission in endemic areas. Recently, a single dose combination of ivermectin (IVM), diethylcarbamazine (DEC), and albendazole (ALB) was shown to be markedly more effective than the standard two-drug regimens (DEC or IVM, plus ALB) for achieving long-term clearance of microfilaremia. OBJECTIVE AND METHODS: To provide context for the results of a large-scale, international safety trial of MDA using triple drug therapy, we searched Ovid Medline for studies published from 1985–2017 that reported adverse events (AEs) following treatment of LF with IVM, DEC, ALB, or any combination of these medications. Studies that reported AE rates by treatment group were included. FINDINGS: We reviewed 162 published manuscripts, 55 of which met inclusion criteria. Among these, 34 were clinic or hospital-based clinical trials, and 21 were community-based studies. Reported AE rates varied widely. The median AE rate following DEC or IVM treatment was greater than 60% among microfilaremic participants and less than 10% in persons without microfilaremia. The most common AEs reported were fever, headache, myalgia or arthralgia, fatigue, and malaise. INTERPRETATION: Mild to moderate systemic AEs related to death of microfilariae are common following LF treatment. Post-treatment AEs are transient and rarely severe or serious. Comparison of AE rates from different community studies is difficult due to inconsistent AE reporting, varied infection rates, and varied intensity of follow-up. A more uniform approach for assessing and reporting AEs in LF community treatment studies would be helpful. Public Library of Science 2018-05-16 /pmc/articles/PMC5973625/ /pubmed/29768412 http://dx.doi.org/10.1371/journal.pntd.0006454 Text en © 2018 Budge et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Budge, Philip J.
Herbert, Carly
Andersen, Britt J.
Weil, Gary J.
Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
title Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
title_full Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
title_fullStr Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
title_full_unstemmed Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
title_short Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
title_sort adverse events following single dose treatment of lymphatic filariasis: observations from a review of the literature
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973625/
https://www.ncbi.nlm.nih.gov/pubmed/29768412
http://dx.doi.org/10.1371/journal.pntd.0006454
work_keys_str_mv AT budgephilipj adverseeventsfollowingsingledosetreatmentoflymphaticfilariasisobservationsfromareviewoftheliterature
AT herbertcarly adverseeventsfollowingsingledosetreatmentoflymphaticfilariasisobservationsfromareviewoftheliterature
AT andersenbrittj adverseeventsfollowingsingledosetreatmentoflymphaticfilariasisobservationsfromareviewoftheliterature
AT weilgaryj adverseeventsfollowingsingledosetreatmentoflymphaticfilariasisobservationsfromareviewoftheliterature